贝瑞基因:2024年报净利润-1.92亿 同比增长55.04%

Financial Performance - The company reported a basic earnings per share of -0.5443 yuan for 2024, an improvement of 54.96% compared to -1.2084 yuan in 2023 [1] - The net profit for 2024 was -1.92 billion yuan, showing a 55.04% increase from -4.27 billion yuan in 2023 [1] - Operating revenue decreased by 6.34% to 10.78 billion yuan in 2024 from 11.51 billion yuan in 2023 [1] - The return on equity improved to -10.87% in 2024 from -20.51% in 2023, reflecting a 47% increase [1] - The net asset per share decreased by 9.87% to 4.75 yuan in 2024 from 5.27 yuan in 2023 [1] Shareholder Structure - The top ten unrestricted shareholders hold a total of 10,376.77 million shares, accounting for 31.74% of the circulating shares, a decrease of 328.32 million shares from the previous period [2] - Chengdu Tianxing Instrument (Group) Co., Ltd. remains the largest shareholder with 4,400.20 million shares, representing 13.46% of total share capital [3] - New entrants in the top ten shareholders include Chengdu Beirui Hekang Gene Technology Co., Ltd. and Huatai-PineBridge Fund Management Co., Ltd. [3]